<SEC-DOCUMENT>0001144204-17-057408.txt : 20171213
<SEC-HEADER>0001144204-17-057408.hdr.sgml : 20171213
<ACCEPTANCE-DATETIME>20171109061029
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-17-057408
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20171109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-839-5200

	MAIL ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 59px; width: 168px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">Boston&nbsp;&nbsp;&nbsp;Brussels&nbsp;&nbsp;&nbsp;Chicago&nbsp;&nbsp;&nbsp;Dallas&nbsp;&nbsp;&nbsp;D&uuml;sseldorf&nbsp;&nbsp;&nbsp;Frankfurt&nbsp;&nbsp;&nbsp;Houston&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;Los Angeles&nbsp;&nbsp;&nbsp;Miami</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Mark J. Mihanovic</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Milan&nbsp;&nbsp;&nbsp;Munich&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;Orange County&nbsp;&nbsp;&nbsp;Paris&nbsp;&nbsp;&nbsp;Rome&nbsp;&nbsp;&nbsp;Seoul&nbsp;&nbsp;&nbsp;Silicon Valley&nbsp;&nbsp;&nbsp;Washington, D.C.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Attorney at Law</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">mmihanovic@mwe.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Strategic alliance with MWE China Law Offices (Shanghai)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 650 815 7438</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 8, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>VIA EDGAR</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt">Attention:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Kim McManus</FONT><BR>
<FONT STYLE="font-size: 10pt">Senior Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Apollo Medical Holdings, Inc.</FONT><BR>
<FONT STYLE="font-size: 10pt">Amendment No. 1 to Registration Statement on Form&nbsp;S-4</FONT><BR>
<FONT STYLE="font-size: 10pt">Filed October 30, 2017</FONT><BR>
<FONT STYLE="font-size: 10pt">File No.&nbsp;333-219898</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Ms.&nbsp;McManus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of
our client, Apollo Medical Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), we hereby provide
responses to comments (the &ldquo;<U>Comments</U>&rdquo;) of the Staff (the &ldquo;<U>Staff</U>&rdquo;) of the Securities and
Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) issued in its letter dated November 6, 2017
(the &ldquo;<U>Letter</U>&rdquo;) regarding the Company&rsquo;s above-referenced Registration Statement on Form&nbsp;S-4 (as amended, the &ldquo;<U>Registration Statement</U>&rdquo;).&nbsp; Contemporaneous with this filing, the Company is filing on
the EDGAR system an Amendment No.&nbsp;2 to the Registration Statement on Form&nbsp;S-4 (&ldquo;<U>Amendment No.
2</U>&rdquo;) reflecting the responses of the Company below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
responses are numbered to correspond to the Comments as numbered in the Letter.&nbsp; For your convenience, each of the Comments
contained in the Letter have been restated in bold below in their entirety, with the Company&rsquo;s corresponding response set
forth immediately under such comment.&nbsp; In the responses below, page&nbsp;number references are to Amendment No. 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Background of the Merger, page 120</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>We note your discussion on page 128 of negotiations taking place in September 2017 regarding possible amendments to the Merger Agreement. You state that during the course of these negotiations, ApolloMed received an unsolicited acquisition offer from a NASDAQ-listed company. Please revise to discuss what consideration ApolloMed gave to this unsolicited offer. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I></B>: In response
to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 128.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Opinion of ApolloMed&rsquo;s Financial
Advisor, page 133</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>We note your response to comment 11. Since the discounted cash flow analysis is based on the projected future cash flows of the company, it appears that the forecasts are material to place this analysis in context and should be disclosed. To the extent such projections no longer reflect management&rsquo;s view of future performance, or are not consistent with actual performance given the passage of time, please explain why the projections are no longer valid and expand disclosure of related risks, as appropriate. Please also revise the discussion of Vantage Point&rsquo;s opinion, which similarly appears to rely on management projections and/or forecasts.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I>: </B>The Company
respectfully submits that the projections are no longer valid because a significant period of time has passed which has caused
the Company&rsquo;s actual results to differ materially from the results forecasted in the financial projections. In response to
the Staff&rsquo;s Comment, the Company has also revised its disclosure of related risks on page 44. The NMM language with respect
to the NMM/Vantage Point forecasts is reflected in the revised disclosure on page 44.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Exhibits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>We note your response to comment 4 of our prior letter in which you have revised you disclosure throughout to state that all the issued and outstanding shares of capital stock of MMG will be sold for $100 under the Stock Purchase Agreement between Warren Hosseinion and APC-LSMA.&nbsp;&nbsp;Under an appropriate heading, please revise to provide greater details regarding the material terms of this agreement.&nbsp;&nbsp;Please also file this agreement as an exhibit or tell us why you believe you are not required to do so.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I></B>: In response
to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 172 under the header &ldquo;Maverick Stock Purchase
Agreement&rdquo; to provide greater details regarding the material terms of the Stock Purchase Agreement and has filed the Stock
Purchase Agreement as Exhibit 10.96 to Amendment No. 2.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Please revise your draft legal opinion to
remove the assumption contained in subsection (ii) in the second paragraph on page 2.&nbsp;&nbsp;This assumption with respect
to the number of authorized shares is overly broad.&nbsp;&nbsp;Please refer to Staff Legal Bulletin No. 19. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I></B>: In response
to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 2 of the legal opinion, filed as Exhibit 5.1 to Amendment
No. 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should you have any
questions concerning any of the foregoing, please contact me by telephone at (650) 815-7438.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Mark J. Mihanovic</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Mark J. Mihanovic</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">McDermott Will &amp; Emery LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">Cc:</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Warren Hosseinion Apollo Medical Holdings, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ *@# 2(  A$! Q$!_\0
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M->./"/C>(82&<6MTP'5,YQ^*M(*]$\70QZSI]KH&\^7J\GE2E&P?(52[D'W
M"_\  ZSOBQH/_"0_#;5[9$W3P1_:H?7='\QQ]5W#\:R/A'JTOBG1+'59]Y_L
MZQ7306'WI0<R,/7*K#SZYH R_@7J$^GQ:[X+OV_TO1[MB@/="2&Q[;AG_@==
MWI4JOJOB'77CED59!9Q".,NQC@!W;0.3^\>08'I7FGCJ<_#SXT:9XM2-S8ZM
M;M!=)&,EG "X_P#11_ UZ[X=T]]+\/V-I-S.D8:8YZRM\SG\6+&@#EOAQ)X1
MDN?$!\+V5W;2?:Q]N^THR$R?-\H#'( .[C QFLWP/_R6/XA_[UI_Z :=\,/^
M1N^(7_89/_LU-\#_ /)8_B'_ +UI_P"@&@!VD_\ )P_B#_L#1?\ H25U_C2Z
MU*Q\%:S=:0"=0BM'>':,D$#J!W(&2/<5R&D_\G#^(/\ L#1?^A)6IXLUB2;Q
MKX>\)&X:UM-266:YD1MKS*@R(5;MN/7'.!@8S0!B^'K^VO=1\.:AX:O;HV M
MFEUNXN+AGB(*?*LA<X,V_P!.0,YX(KTNWOK2[9EMKJ"9E&6$<@8CZXKR6_5/
MA/XDFB-G]H\%ZX6VVVT,EK=8^Y@\!7QWX_[YY[_P9X2T_P (Z##:6EI!%<.N
M^YDC49DD/)YZD D@#L,4 ><_':1(M:\#2R,%1-09F8]  T637H:^-='N_$.G
M:-I]Y;WD]V)&<1OGRT5"<_B<#\:\^^.9 U[P'SC_ (F+'_QZ*O6;K3(+O4;"
M^DR)K)G:(C'\:E2#[<_H* ,ZYN=-\"^%4/D7;:=8IM"P1-,R( 3D@?P@#KT%
M9D?Q(TN\TF+4=,T[5M3A:(32"RM@YA!&</\ ,!NQ_""3[4NKZ]!K/ASQM;0*
MIBTV">U:4-D._D;F'M@MCZ@TWX4(J?"WP^%4*#;9.!C)+')H L6_Q T;4=-M
M[S1TO-6:>/S!;V,.Z1%R0=X) 3D$?,1G'&:O^&?%6F>*[*:YTXS*UO*8;BWN
M(S'+!(.JNIZ&N.^!D44?@.X9(T5GU*XW$#!." ,_A6'HLEW#%\8'L=PN4N)F
MBV]0VR3D>] 'H9\:6<L-W<Z?8:AJ5G:,R375I$K)E?O!,L#)COM!_$TZ]\<:
M)9>%H_$@EGNM+D3>LUK \O'<G ^7&,'=C!ZUR_PKT2UO?AEHD\6H:E&&A8,D
M-XZ*&#L&P >.<U?U[PYI?A7X2^)-,T>)HK5;*Y?8TK/AF0YY8DCZ>] %B7XG
M^'XHM/N E])9WKQ1_:X[?,,,D@#*CMGAL$9 SCO5W_A/-)_X2H>&C#J U0G(
MB-HX!3.-X;H4]Z@^&EK OPP\.QB)-ALXY-I7C<?F)^N3FL3XLV%QI\.E>.-,
MC+7V@3AY57K+;,<.I_/\ 6H Z_6_$UIH%Q:0W5M?RM=OY<)MK9I0SX)V\=#A
M2?H#16?I-];^*O$*:O:N)=-L;95MG'1II5#,?JL91?\ @;"B@#J6571D8!E8
M8(/0BL;PIX9LO"'A^#1K NT$3.^Y\;F+,6YQ]<?0"MJB@#$\2>%K#Q0FG+?!
MO] O8[R/;CED/W3G^$]#6O<1--;R1)-)"S*0)(\;E]QD$9^H-244 <GH'@*U
M\.:CJ%]9:QJS2Z@[2W0FDC=9)#GY\;."-Q/''3MQ1HO@.UT/Q%>:Y;ZOJLMY
M?$&[$TD;)-CID!!C&>,8KK** .1M/ %M9^*Y?$J:UJ[:E,@CE9Y(BDD8Q\A7
MR\8^4=,'WJYXM\%Z7XQM;=+YIX+FTD\VUO+5]DL#^JG\!Q[#TKHJ* .0;X?6
M6HZ?):>(]1O]>#H44WC*HB_VD5  '_VCD^_)JQX?\'R:%) )/$.K:A;6JE;6
MWNI%VQC&.2J@O@<#<2!Z5T]% '#^)OA?IGBZ_AN]7U?6)&MV9K=(YHT6')S\
MH">PY.3P*U9?"MU-;&!O%>OA2NTLDD*O_P!]"+(/O71T4 <;IWPWTK2?"E]X
M=L;_ %.*UOI7EN9?.4RR;U"LNXKT('IGWK1T3PE%X?\ #AT.PU74EME&V&1W
MC:2 9SA3LQZ]0?:NAHH YCPKX(L_!VG7-AIFHZBUO.6<+/(C^6YZNIV=>G7(
M]J9X=\"6?AK5K[4;35-3FDOY#+=I<2(R3.<_,0$!!Y/0BNJHH Y.Q\$#1)IQ
MX?UB\TNRN)#*]DB1R1(QZF/>I*9]!Q[5:OO!ME>^')M#%Y?6]M<%S=212+YM
MR7^\79E.<]\8].G%=%10!C^&_#T7AC2H],MKZ\N;6%0D*W3*QC4=@54<?7-2
M>([NRLO#U_+J*+);&%D:%CCSMPP(QZELX ]ZU*X'Q%86VH_%KPNEY&9H[>VG
MN(HV8[5E4C:^W.,CUH Z#P9X=B\*^$=.T>-0&@B'FD<YD/S.<]^2:*WJ* /_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
